NFlection Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
867 Boylston St Fl 5, Boston, Massachuse...Website
www.nflection.comRevenue
<$5 MillionIndustry
About NFlection Therapeutics
We are initially focused on the treatment of cutaneous neurofibromas in neurofibromatosis type 1, disfiguring congenital birthmarks (including keratinocytic epidermal nevi and nevus sebaceous), and the prevention of immunosuppressant-mediated squamous cell carcinoma. We are funded by F-Prime Capital, venBio, and the Children's Tumor Foundation and have assembled a proven team of experienced drug development professionals and key opinion leaders to develop a "soft" (metabolically labile) topical MEK inhibitor to treat disfiguring RAS-mediated conditions of the skin. NFlection Therapeutics logoExplore more
NFlection Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to NFlection Therapeutics
Compare insights from companies similar to NFlection Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NFlection Therapeutics Tech Stack
A closer look at the technologies used by NFlection Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NFlection Therapeutics
Sign Up For FreeTo access detailed company insights
We are initially focused on the treatment of cutaneous neurofibromas in neurofibromatosis type 1, disfiguring congenital birthmarks (including keratinocytic epidermal nevi and nevus sebaceous), and the prevention of immunosuppressant-mediated squamous cell carcinoma. We are funded by F-Prime Capital, venBio, and the Children's Tumor Foundation and... Read More
